The results of a recent survey revealed that unvaccinated Americans were much less inclined than those who had been vaccinated to indicate they would take Pfizer’s COVID-19 tablet.
The health website Stat and a Harris Poll study reported that 48 percent of unvaccinated respondents stated they would be “not at all” or “extremely unlikely” to take Pfizer’s tablet if a health practitioner recommended it to them.
People who had been vaccinated, on the other hand, were significantly more receptive to taking the medication. When asked whether they would be “extremely” or “somewhat” inclined to take the drug if recommended by a doctor, 91 percent of those who had had vaccinations responded affirmatively.
According to the results of the survey of American adults, 52 percent of all respondents indicated they had read “a lot” or “a little bit” about Pfizer’s Paxlovid pill, which was approved for emergency use by the Food and Drug Administration (FDA) on December 22.
On the other hand, 48% said they had read “nothing at all” or “not too much” about the medication.
Out of all those who claimed they were acquainted with the pill, 84 percent of all respondents said they were confident that the medication would be either “very” or “somewhat” successful in combating the pandemic.
Ninety percent of respondents who had heard of the pill believed it would be beneficial in the battle against the epidemic, compared to just 56 percent of unvaccinated persons who had heard of the drug and believed it would be beneficial in handling the public health problem.
23 percent of those who have been vaccinated and are acquainted with Pfizer’s therapy think that the tablet would lessen their need for vaccinations and boosters, according to the survey.
Unvaccinated responders acquainted with the pill make the same mistake as 40% of those who are not.
Paxlovid was the first antiviral COVID-19 tablet approved by the FDA for infected persons to take at home. It was developed by the pharmaceutical company Pfizer.
The tablet is available to high-risk persons 12 and older who weigh at least 88 pounds and have tested positive for the virus, but they must have a doctor’s prescription to do so.
Patients who take Paxlovid within five days after reporting COVID-19 symptoms had an 88 percent lower chance of hospitalization or mortality when compared to those who take a placebo, according to data from a clinical investigation.
The FDA approved the Pfizer tablet the same day it approved molnupiravir, an antiviral medication developed by Merck/Ridgeback Biotherapeutics to treat COVID-19, with the same limitations as the Pfizer pill.
However, Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, has stated that molnupiravir should only be used in “situations where other FDA-authorized treatments for COVID-19 are inaccessible or are not clinically appropriate” and that it should not be used in “situations where other FDA-authorized treatments for COVID-19 are not clinically appropriate.”
Stat revealed that the Harris Poll study was performed before the FDA approved the Merck/Ridgeback Biotherapeutics pill.
Please keep checking our website for more news!